경피적 내시경 위루술 기기 시장 : 기기 유형, 최종사용자, 유통 채널, 재료, 절차, 연령층별 - 세계 예측(2026-2032년)

The Percutaneous Endoscopic Gastrostomy Device Market was valued at USD 2.12 billion in 2025 and is projected to grow to USD 2.24 billion in 2026, with a CAGR of 6.58%, reaching USD 3.32 billion by 2032.

An authoritative orientation to modern percutaneous endoscopic gastrostomy device dynamics that clarifies clinical priorities, procurement trade-offs, and lifecycle considerations

Percutaneous endoscopic gastrostomy devices occupy a vital role at the intersection of clinical nutrition, long-term care, and minimally invasive access procedures. These devices are the conduit through which enteral nutrition, medication administration, and gastric decompression are performed, and as such their design, material composition, and delivery model have direct implications for patient outcomes, caregiver workflows, and institutional budgets. Over recent years, clinical practice has shifted toward earlier discharge, greater use of home-based care, and heightened sensitivity to device-related complications, driving greater scrutiny of device usability, durability, and infection control features.

Clinicians and procurement leaders now evaluate gastrostomy devices not merely on initial placement success but on lifecycle factors such as replacement frequency, ease of bedside exchange, patient comfort, and compatibility with ambulatory and home-care settings. Simultaneously, manufacturers have responded with differentiated designs that prioritize low-profile profiles, modular components, and simplified placement techniques. This evolution invites a reassessment of procurement criteria, clinical pathways, and partnership models across hospital systems, ambulatory surgery centers, and home healthcare providers. In short, the device category is maturing from a commoditized supply item to a strategic clinical asset that requires integrated consideration of clinical utility, supply chain resilience, and post-market support.

How clinical shifts, materials innovation, and evolving distribution models are collectively redefining product design priorities and care delivery pathways for gastrostomy access devices

The landscape for percutaneous endoscopic gastrostomy devices is being reshaped by converging forces in clinical practice, device innovation, and healthcare delivery models. Minimally invasive procedural techniques and enhanced endoscopic visualization are reducing procedural time and complication rates, which in turn is creating demand for devices optimized for rapid placement and secure retention. Concurrently, the migration of procedures toward ambulatory surgery centers and home healthcare settings is prompting manufacturers and providers to prioritize user-friendly interfaces and low-profile options that reduce caregiver training burdens and support outpatient pathways.

Materials science advances and a greater emphasis on infection prevention are establishing new baselines for device performance. Polyurethane and silicone formulations are being refined to balance flexibility, tensile strength, and biocompatibility, while incremental improvements in balloon retention and bumper designs are addressing leakage and tissue irritation concerns. On the commercial side, distribution models are shifting; direct sales relationships with large integrated health systems coexist with e-commerce and distributor channels that target smaller ambulatory and homecare purchasers. Taken together, these developments are moving the market toward modularity, differentiated clinical value propositions, and closer alignment between device features and care delivery settings.

Implications of impending United States tariff measures for 2025 on supply chain resilience, procurement strategies, and cost-containment priorities across the gastrostomy device ecosystem

The imposition and escalation of tariffs can have ripple effects across medical device supply chains, and the announced tariff measures in the United States for 2025 introduce a new variable for manufacturers, distributors, and healthcare purchasers. Tariffs increase landed costs for imported components and finished devices, prompting manufacturers to reassess supplier footprints, pricing strategies, and contract terms. In response, some manufacturers may accelerate reshoring, nearshoring, or dual-sourcing strategies to reduce exposure to tariff volatility, while others may pursue cost containment through design simplification or alternative materials that are less exposed to tariffed categories.

Healthcare providers and system purchasers will feel these effects through tighter procurement negotiations, potential repricing of consumables, and renewed emphasis on total cost of ownership when choosing between balloon retention and non-balloon retention devices or between polyurethane and silicone materials. Supply chain teams are therefore re-evaluating inventory policies, safety stock levels, and long-term supplier agreements to manage both cash flow and availability risk. Regulatory compliance and customs administration costs add another layer of operational complexity, requiring closer coordination among procurement, legal, and logistics functions. Ultimately, tariff-driven cost pressures may accelerate consolidation among suppliers and incentivize innovation that reduces per-procedure resource intensity, but they will also raise short-term procurement and budgeting challenges for healthcare buyers.

Integrated segmentation intelligence that maps device types, care settings, distribution pathways, material choices, procedural contexts, and patient demographics to clinical and commercial priorities

Segmentation insights reveal that product, care setting, distribution pathway, material selection, procedural context, and patient demography each present distinct dynamics that influence clinical adoption, procurement decisions, and innovation priorities. Based on device type, devices fall into balloon retention and non-balloon retention categories; balloon retention devices further differentiate into low-profile balloon designs that emphasize comfort and outpatient suitability and standard balloon devices that prioritize established clinical familiarity, while non-balloon retention solutions divide into external bumper devices that offer ease of replacement and internal bumper devices that emphasize secure long-term anchoring. These device-level distinctions inform clinician preference for initial placement versus replacement procedures and shape training and inventory policies.

Based on end user, the care environment shifts requirements: ambulatory surgery centers demand devices that facilitate quick turnover and same-day discharge protocols, home healthcare settings require devices with simplified maintenance and caregiver-friendly replacement options, and hospitals prioritize devices that integrate with complex case mixes and longer inpatient stays. Based on distribution channel, direct sales relationships support customized training and bundled service agreements with large systems, e-commerce platforms enable rapid replenishment for decentralized buyers, and medical distributors consolidate logistics for smaller purchasers. Based on material, polyurethane devices and silicone devices offer differentiated trade-offs in flexibility, patient comfort, and durability, affecting clinician selection and replacement cadence. Based on procedure, the distinct requirements of initial placement versus replacement procedures drive choices around device profile, insertion technique compatibility, and ancillary accessory availability. Based on age group, adult patients and pediatric patients present divergent anatomical and care considerations that influence device dimensioning, retention mechanism choice, and caregiver instruction sets. Integrating these segmentation layers yields a nuanced picture of where product innovation, targeted marketing, and supply chain optimization will generate the greatest clinical and commercial return.

Regional strategic considerations and differentiated adoption pathways that reconcile clinical needs, regulatory frameworks, and distribution realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape procurement priorities, clinical protocols, and the competitive environment in ways that materially influence product strategy. In the Americas, a combination of mature hospital systems, growing ambulatory surgery capabilities, and a sizable home healthcare sector creates demand for devices that balance clinical robustness with ease of outpatient and home use, and payers and providers are increasingly focused on procedures that reduce length of stay and post-procedural complications. In Europe, Middle East & Africa, regulatory heterogeneity and varying levels of care infrastructure produce differentiated adoption pathways: high-acuity urban centers often adopt advanced device features rapidly, whereas remote or resource-constrained settings prioritize cost-effectiveness and supply chain reliability. In Asia-Pacific, expanding healthcare access, rising surgical volumes, and growing investment in ambulatory and home care infrastructure are driving demand for low-profile, cost-efficient solutions that can scale across diverse clinical environments.

These regional patterns influence everything from materials selection and device form factor to distribution strategies and post-market support models. For multinational manufacturers, successful regional playbooks blend centralized R&D and regulatory expertise with localized distribution partnerships, training programs, and value demonstration activities that match the operational realities of each geography. For regional suppliers and distributors, competitive differentiation often hinges on service quality, aftercare support, and the ability to tailor solutions to specific patient demographics and procedural norms.

Competitive and strategic company-level perspectives that describe how incumbents, niche innovators, contract manufacturers, and distribution partners shape product leadership and market access

The competitive landscape for gastrostomy devices is characterized by a mix of incumbent medical device manufacturers, specialized device innovators, contract manufacturers, and distribution-focused players. Incumbent manufacturers leverage established clinical relationships and broad service capabilities to secure preferred supplier status within hospital systems and integrated delivery networks, while specialized innovators focus on niche differentiation such as low-profile delivery systems, novel retention mechanisms, or materials optimized for reduced biofouling. Contract manufacturers and component suppliers play an increasingly strategic role, enabling faster prototyping and scale-up while also buffering large original equipment manufacturers against supply chain shocks.

Commercial success increasingly depends on integrated go-to-market strategies that combine clinician education, evidence generation through observational and real-world studies, and flexible distribution models tailored to ambulatory, hospital, and home healthcare channels. Partnerships that bundle training, remote monitoring, and consumable supply agreements create sticky relationships with care providers. Moreover, companies that invest in post-market surveillance and iterative product improvements demonstrate stronger clinician acceptance and lower rates of device-related complications. Financial discipline, strategic M&A to acquire complementary technologies, and investment in regulatory expertise to navigate multinational approval pathways are recurring themes among market leaders seeking to scale globally while maintaining localized support.

Actionable strategic priorities for manufacturers and provider partners to harmonize product development, distribution resilience, and clinical evidence programs for accelerated adoption

Industry leaders should pursue a multi-pronged agenda that aligns product design with care pathway evolution, secures supply chain flexibility, and accelerates evidence generation to support adoption. Prioritize device attributes that reduce procedural time and caregiver burden while maintaining retention reliability, focusing on low-profile and modular designs that simplify both initial placement and replacement procedures. Simultaneously, evaluate materials choices through the dual lenses of patient comfort and lifecycle durability, selecting formulations and manufacturing processes that minimize replacement frequency and reduce the total cost of ownership for institutional buyers.

On the commercial front, cultivate hybrid distribution models that combine direct relationships with integrated health systems and robust partnerships with e-commerce platforms and medical distributors to serve ambulatory and homecare clients. Strengthen supply chain resilience by diversifying supplier bases, considering nearshoring for critical components, and implementing longer-term purchasing agreements where appropriate to hedge against tariff-related volatility. Invest in targeted clinical evidence generation, including real-world data and comparative usability studies, to demonstrate value in ambulatory and homecare settings. Finally, develop comprehensive training and support packages for clinicians and caregivers, and align reimbursement and procurement teams early in product introduction to minimize barriers to adoption and ensure smooth integration into clinical pathways.

Research approach that integrates clinician engagements, supply chain analysis, and literature synthesis to validate practical insights without relying on quantitative market estimates

The research underlying this analysis combines primary qualitative engagement with domain experts, clinicians, procurement leaders, and supply chain specialists alongside a rigorous review of peer-reviewed clinical publications, regulatory guidance documents, and industry technical literature. Primary engagements included structured interviews and targeted discussions that illuminated real-world decision criteria, device handling considerations in ambulatory and home settings, and procurement contracting practices. Secondary research synthesized clinical outcome studies, materials science literature, and relevant regulatory filings to triangulate design implications and safety considerations.

Analytical steps included mapping device segmentation against care pathways and regional adoption patterns, assessing distribution channel economics, and evaluating material trade-offs with respect to clinical comfort and durability. Findings were validated through iterative consultations with practicing clinicians and supply chain professionals to ensure practical applicability. Throughout the research, emphasis was placed on synthesizing actionable insights rather than producing quantitative estimates, ensuring recommendations are grounded in observable trends, verified clinical considerations, and operational constraints that influence procurement and product development decisions.

Concluding perspective on the convergence of clinical innovation, supply chain resilience, and evidence-driven commercialization that will define next-generation gastrostomy device success

In conclusion, percutaneous endoscopic gastrostomy devices are transitioning from commodity items to strategic clinical technologies whose design, material selection, and distribution model materially affect clinical workflows and patient experience. Device-level distinctions between balloon retention and non-balloon retention technologies, nuanced material trade-offs between polyurethane and silicone, and the divergent requirements of initial placement versus replacement procedures create clear vectors for targeted innovation. The migration of care into ambulatory surgery centers and home healthcare settings amplifies the need for low-profile, user-friendly devices and comprehensive support offerings that reduce caregiver burden and enable safe home management.

At the same time, commercial realities such as tariff-related supply chain pressures and evolving distribution channels demand that manufacturers and purchasers adopt more sophisticated sourcing, pricing, and evidence-generation strategies. Companies that successfully align product development with care delivery trends, secure diversified and resilient supply chains, and demonstrate value through clinical and real-world evidence will be best positioned to lead in this evolving category. The path forward hinges on a pragmatic blend of design excellence, operational robustness, and close collaboration with providers to ensure devices meet the needs of clinicians, caregivers, and patients alike.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Percutaneous Endoscopic Gastrostomy Device Market, by Device Type

• 8.1. Balloon Retention Devices
• 8.2. Non-Balloon Retention Devices

9. Percutaneous Endoscopic Gastrostomy Device Market, by End User

• 9.1. Ambulatory Surgery Centers
• 9.2. Home Healthcare Settings
• 9.3. Hospitals

10. Percutaneous Endoscopic Gastrostomy Device Market, by Distribution Channel

• 10.1. Online
• 10.2. Offline

11. Percutaneous Endoscopic Gastrostomy Device Market, by Material

• 11.1. Polyurethane Devices
• 11.2. Silicone Devices

12. Percutaneous Endoscopic Gastrostomy Device Market, by Procedure

• 12.1. Initial Placement
• 12.2. Replacement Procedures

13. Percutaneous Endoscopic Gastrostomy Device Market, by Age Group

• 13.1. Adult Patients
• 13.2. Pediatric Patients

14. Percutaneous Endoscopic Gastrostomy Device Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Percutaneous Endoscopic Gastrostomy Device Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Percutaneous Endoscopic Gastrostomy Device Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Percutaneous Endoscopic Gastrostomy Device Market

18. China Percutaneous Endoscopic Gastrostomy Device Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. Applied Medical Technology
• 19.6. Avanos Medical
• 19.7. Boston Scientific
• 19.8. Cardinal Health
• 19.9. ConMed
• 19.10. Cook Group
• 19.11. Danone
• 19.12. Fresenius Kabi
• 19.13. GBUK Group
• 19.14. Nestle